NTRA
Natera Inc

2,318
Mkt Cap
$31.96B
Volume
1.36M
52W High
$246.90
52W Low
$125.38
PE Ratio
-101.55
NTRA Fundamentals
Price
$231.95
Prev Close
$231.05
Open
$231.50
50D MA
$205.18
Beta
1.23
Avg. Volume
1.8M
EPS (Annual)
-$1.53
P/B
25.48
Rev/Employee
$382,704.33
Loading...
Loading...
News
all
press releases
Gilder Gagnon Howe & Co. LLC Decreases Stake in Natera, Inc. $NTRA
Gilder Gagnon Howe & Co. LLC lessened its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 11.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange...
MarketBeat·28m ago
News Placeholder
More News
News Placeholder
Bellevue Group AG Raises Stock Position in Natera, Inc. $NTRA
Bellevue Group AG grew its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 30.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and...
MarketBeat·3h ago
News Placeholder
AQR Capital Management LLC Boosts Holdings in Natera, Inc. $NTRA
AQR Capital Management LLC lifted its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 44.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional...
MarketBeat·3h ago
News Placeholder
Maverick Capital Ltd. Reduces Position in Natera, Inc. $NTRA
Maverick Capital Ltd. trimmed its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 8.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·23h ago
News Placeholder
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced their...
Business Wire·23h ago
News Placeholder
Natera New Test Data Could Change How Doctors Manage Breast Cancer
Natera's PALLAS study data show MRD status strongly predicts five-year recurrence risk in stage II III HR+/HER2- breast cancer based on Signatera testing.read more...
Benzinga·2d ago
News Placeholder
Frontier Capital Management Co. LLC Has $65.04 Million Position in Natera, Inc. $NTRA
Frontier Capital Management Co. LLC decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 3.4% in the 2nd quarter, according to its most recent 13F filing with the...
MarketBeat·2d ago
News Placeholder
Natera Unveils MRD Data From Phase III PALLAS Trial In HR+/HER2- Breast Cancer
(RTTNews) - Natera Inc. (NTRA) announced initial translational research results from the international randomized Phase III PALLAS study. The findings were presented at the San Antonio Breast Cancer...
Nasdaq News: Markets·2d ago
News Placeholder
Phase III PALLAS Study Shows Signatera MRD Testing Provides Powerful PostSurgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2 Breast Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group...
Business Wire·2d ago
News Placeholder
Cerity Partners LLC Boosts Holdings in Natera, Inc. $NTRA
Cerity Partners LLC lifted its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 13.9% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor...
MarketBeat·3d ago

Latest NTRA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.